Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir

被引:135
|
作者
Nolan, D
Upton, R
McKinnon, E
John, M
James, I
Adler, B
Roff, C
Vasikaran, S
Mallal, S [1 ]
机构
[1] Royal Perth Hosp, Dept Clin Immunol, Ctr Clin Immunol & Biomed Stat, Perth, WA 6000, Australia
[2] Murdoch Univ, Murdoch, WA 6150, Australia
[3] Royal Perth Hosp, Dept Nucl Med, Perth, WA, Australia
[4] Royal Perth Hosp, Dept Core Clin Pathol & Biochem, Perth, WA, Australia
关键词
bone mineral density; HAART; indinavir; lipodystrophy syndrome; nelfinavir; protease inhibitors; osteopenia; osteoporosis; subcutaneous fat wasting;
D O I
10.1097/00002030-200107060-00009
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background and objectives: To determine the factors contributing to changes in bone mineral density (BMD) over time in HIV-infected patients receiving highly active antiretroviral therapy (HAART). Methods: Analyses of lumbar spine BMD in 183 male Caucasian participants in the Western Australian HIV Cohort study, comprising a longitudinal analysis of data from 54 patients on stable HAART regimens, and a cross-sectional analysis comparing data from 131 protease inhibitor (PI)-treated patients and 52 PI-naive (including 28 antiretroviral treatment-naive) patients. Results: Average lumbar spine BMD remained stable or increased over the time frame considered. Although there was no evidence of a change of average BMD over time in patients receiving nelfinavir (P = 0.92), there was evidence of increasing bone density in the indinavir group (average increase, 0.31 z-score per year; P < 0.001). Lower initial z-scores in the longitudinal analysis were significantly associated with lower pre-HAART BMI (P = 0.003), consistent with results of the cross-sectional analysis in which lowest BMI prior to initial dual X-ray absorptiometry scan was associated with decreased BMD (P = 0.02, overall group). Although PI therapy was also associated with decreased BMD in a univariate analysis of the cross-sectional data (P = 0.04), this effect was abrogated in a multiple linear regression analysis (P = 0.11) with lowest BMI remaining significant (P = 0.04). Conclusions: We found no evidence, overall, of accelerated bone loss in patients treated with nelfinavir- or indinavir-containing HAART regimens, and propose that indinavir therapy may be associated with an increase in bone mineral density over time. Pre-HAART BMI was an independent and powerful determinant of an individual's initial z-score in the longitudinal analysis, and adjustment for this effect in a cross-sectional analysis abrogated the association between P1 therapy and decreased lumbar spine z-score. (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:1275 / 1280
页数:6
相关论文
共 50 条
  • [41] Association of Adipokines With Bone Mineral Density in HIV-Infected and HIV-Uninfected Women
    Sharma, Anjali
    Ma, Yifei
    Scherzer, Rebecca
    Wheeler, Amber L.
    Cohen, Mardge
    Gustafson, Deborah R.
    Keating, Sheila M.
    Yin, Michael T.
    Tien, Phyllis C.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 73 (04) : 433 - 437
  • [42] High Variability of Indinavir and Nelfinavir Pharmacokinetics in HIV-infected Patients with a Sustained Virological Response on Highly Active Antiretroviral Therapy
    Cécile Goujard
    Mayeule Legrand
    Xavière Panhard
    Bertrand Diquet
    Xavier Duval
    Gilles Peytavin
    Isabelle Vincent
    Christine Katlama
    Catherine Leport
    Bénédicte Bonnet
    Dominique Salmon-Céron
    France Mentré
    Anne-Marie Taburet
    Clinical Pharmacokinetics, 2005, 44 : 1267 - 1278
  • [43] Pharmacokinetics of indinavir in HIV-infected children
    Burger, DM
    Hugen, PWH
    de Groot, R
    AIDS, 1998, 12 : S93 - S93
  • [44] Pharmacokinetics of indinavir in HIV-infected children
    Burger, DM
    Hugen, PWH
    de Groot, R
    AIDS, 1998, 12 : S10 - S10
  • [45] Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients
    Merry, C
    Barry, MG
    Mulcahy, F
    Halifax, KL
    Back, DJ
    AIDS, 1997, 11 (15) : F117 - F120
  • [46] Assessing the Association between Leptin and Bone Mineral Density in HIV-Infected Men
    Rao, Madhu N.
    Schambelan, Morris
    Tai, Vivaw.
    Abrams, Donald I.
    Khatami, Hootan
    Havel, Peter J.
    Sakkas, Giorgos
    Mulligan, Kathleen
    AIDS RESEARCH AND TREATMENT, 2012, 2012
  • [47] Impact of hypogonadism on bone mineral density and vertebral fractures in HIV-infected men
    Pezzaioli, L. C.
    Porcelli, T.
    Delbarba, A.
    Maffezzoni, F.
    Foca, E.
    Castelli, F.
    Cappelli, C.
    Ferlin, A.
    Quiros-Roldan, M. E.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2022, 45 (02) : 433 - 443
  • [48] Impact of hypogonadism on bone mineral density and vertebral fractures in HIV-infected men
    L. C. Pezzaioli
    T. Porcelli
    A. Delbarba
    F. Maffezzoni
    E. Focà
    F. Castelli
    C. Cappelli
    A. Ferlin
    M. E. Quiros-Roldan
    Journal of Endocrinological Investigation, 2022, 45 : 433 - 443
  • [49] Bone Mineral Density Increases in HIV-Infected Children Treated With Long-term Combination Antiretroviral Therapy
    Bunders, Madeleine J.
    Frinking, Olivier
    Scherpbier, Henriette J.
    van Arnhem, Lotus A.
    van Eck-Smit, Berthe L.
    Kuijpers, Taco W.
    Zwinderman, Aeilko H.
    Reiss, Peter
    Pajkrt, Dasja
    CLINICAL INFECTIOUS DISEASES, 2013, 56 (04) : 583 - 586
  • [50] Low bone mineral density and risk of incident fracture in HIV-infected adults
    Battalora, Linda
    Buchacz, Kate
    Armon, Carl
    Overton, Edgar T.
    Hammer, John
    Patel, Pragna
    Chmiel, Joan S.
    Wood, Kathy
    Bush, Timothy J.
    Spear, John R.
    Brooks, John T.
    Young, Benjamin
    ANTIVIRAL THERAPY, 2016, 21 (01) : 45 - 54